Related Experiment Video

Updated: Aug 21, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

[Current status and future of drug therapy for advanced gastroenteropancreatic neuroendocrine tumors]

Yihebali Chi1, H K Wang1

  • 1Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Zhonghua Yi Xue Za Zhi
|August 19, 2026
PubMed

Insights

The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) is rising, with diverse treatments available. This review explores advanced GEP-NET drug therapy evolution, current challenges, and future precision medicine strategies.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Rising incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET).
  • Increasing diversity in treatment strategies for advanced GEP-NET.
  • Need for systematic review of evolving drug therapies.

Purpose of the Study:

  • To explore the evolution of drug treatment for advanced GEP-NET.
  • To systematically review evidence-based progress in core therapeutic approaches.
  • To analyze current clinical decision-making challenges and future prospects.

Main Methods:

  • Systematic review of evidence-based medical progress.
  • Review of core approaches: somatostatin analogues, targeted therapy, chemotherapy, immunotherapy, PRRT.
  • Analysis of clinical decision-making challenges and expert opinions.

Main Results:

  • Evolution of drug treatment landscape for advanced GEP-NET detailed.
  • Progress in somatostatin analogues, targeted therapy, chemotherapy, immunotherapy, and PRRT outlined.
  • Key challenges identified: treatment sequencing, drug resistance, biomarker development.

Conclusions:

  • Advanced GEP-NET drug therapy is rapidly evolving.
  • Future directions include drug combinations, novel therapies, and precision medicine.
  • Optimizing treatment sequences and overcoming resistance are critical for improved outcomes.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...